

## Curriculum Vitae – Miembro CISOL

Roberto Andrés Escala Cornejo  
Especialista en Oncología Médica  
Código ORCID: <https://orcid.org/0000-0002-6145-7683>

### Información General

---

Lugar y fecha de nacimiento: Guayaquil, 13 de Julio de 1986  
Nacionalidad: ecuatoriana  
Email: robertoescalacornejo@gmail.com

### Titulación Académica y Universitaria

---

- 2019 - Título de Especialista en Oncología Clínica

Salamanca – España

- 1980 – Título en Doctor en Medicina y Cirugía

Facultad de Ciencia Médicas.

Universidad Católica de Santiago de Guayaquil – Ecuador

### Cargo Actual

---

Coordinador del Comité de Investigación de SOLCA (CISOL)  
Hospital SOLCA – Guayaquil  
Guayaquil – Ecuador  
Periodo: Noviembre 2023 - Actualidad

## Publicaciones

---

Número de artículos incluidos en PubMed/MEDLINE:

- Paula González Villarroel, Josep Gumà Padró, Gloria Marquina, Noelia Martínez Jáñez, Emilio Esteban González, Antonio Antón, Miguel Berzosa Sánchez, Alberto Rodrigo Cáceres, Rafael López-López, Roberto Escala Cornejo, Pablo Borrega García, Raquel Marse Fabregat, Beatriz Castelo Fernández, Cristina López Bermudo, Carlos Camps.  
Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study. *Future Oncol.* 2022 Nov;18(35):3913-3927. doi:10.2217/fon-2022-0758.
- Escala-Cornejo R, Olivares-Hernández A, García-Muñoz M, Figuero-Pérez L, Martín-Vallejo J, Miramontes-González JP, et al. Identifying the best Ki67 cut-off determining luminal breast cancer subtypes using immunohistochemical analysis and PAM50 genomic classification. *EMJ Oncol.* 2022. DOI:10.33590/emjoncol/22-00100
- Olivares-Hernández A, Del Barco Morillo E, Miramontes-González JP, Figuero-Pérez L, Pérez-Belmonte L, Martín-Vallejo J, Martín-Gómez T, Escala-Cornejo R, Vidal-Tocino R, Hernández LB, Sarmiento RG, Ludeña de la Cruz MD, Cruz-Hernández JJ, Pérez CP.  
Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy. *Front Biosci (Landmark Ed).* 2022 Mar 8;27(3):88. doi: 10.31083/j.fbl2703088.
- Olivares-Hernández A, Del Barco Morillo E, Parra Pérez C, Miramontes-González JP, Figuero-Pérez L, Martín-Gómez T, Escala-Cornejo R, Bellido Hernández L, González Sarmiento R, Cruz-Hernández JJ, Ludeña de la Cruz MD. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis. *Biomedicines.* 2022 Feb 2;10(2):360. doi: 10.3390/biomedicines10020360
- Figuero-Pérez L, Olivares-Hernández A, Escala-Cornejo RA, Cruz-Hernández. Use of Anakinra in the Treatment of SARS-CoV-2 Severe Respiratory Infection. *Reumatol Clin.* 2022. doi:10.1016/j.reuma.2022.02.003
- Figuero-Pérez L, Olivares-Hernández A, Escala-Cornejo RA, Terán-Brage E, López-Gutiérrez Á, Cruz-Hernández JJ. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab. *Reumatol Clin (Engl Ed).* 2021 Dec;17(10):559-561. doi: 10.1016/j.reumae.2020.06.008.

- Olivares-Hernández A, Figuero-Pérez L, Amores Martín MA, Bellido Hernández L, Mezquita L, Vidal Tocino MDR, López Cadenas F, Gómez-Camínero López F, Escala-Cornejo RA, Cruz Hernández JJ. Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors. *Case Rep Oncol Med*. 2021 Feb 12;2021:6631859. doi: 10.1155/2021/6631859.
- Escala-Cornejo RA, García Muñoz M, Olivares-Hernández A, Sancho de Salas M, Gómez Muñoz MA, Claros Ampuero J, et al. Identifying the best Ki67 cut-off for determining luminal breast cancer subtypes using immunohistochemical analysis and PAM50 genomic classification. *EMJ Oncol*. 2020; 8[1]: 47-48.
- Figuero-Pérez L, Olivares-Hernández A, Escala-Cornejo RA, Cruz-Hernández JJ. Reply to A Lasagna et al. *JCO Oncol Pract*. 2020. <https://doi.org/10.1200/OP.20.00640>.
- Olivares-Hernández A, Escala-Cornejo RA, Figuero-Pérez L, Vidal-Tocino MR, González-Sarmiento R, Cruz-Hernández JJ, et al. Use of C-peptide levels in the diagnosis and prevention of type 1 diabetes mellitus as an immune-related adverse event secondary to treatment with immunotherapy in solid tumors. *J Clin Immunol Immunother*. 2020.6: 034. DOI: 10.24966/CIIT-8844/1000034.
- Figuero-Pérez L, Olivares-Hernández A, Escala-Cornejo RA, Terán-Brage E, López- Gutiérrez A, Cruz-Hernández JJ. Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab. *Reumatol Clin*.2020. <https://doi.org/10.1016/j.reuma.2020.06.003>.
- Figuero-Pérez L, Olivares-Hernández A, Escala-Cornejo RA, Cruz-Hernández JJ. Management of febrile neutropenia associated with SARS-CoV-2 infection in a patient with cancer. *JCO Oncol Pract*. 2020; 16(6): 348-349.
- Olivares-Hernández A, Escala-Cornejo RA, García-Domínguez AR, Cruz-Hernández JJ. Severe Ketoacidosis as the First Clinical Manifestation of Type 1 Diabetes Mellitus Secondary to Immune Checkpoint Inhibitors. *Asian Journal of Oncology*. 2020. 01: 1-46. DOI: 10.1055/s-0040-1710147
- Roberto Escala Cornejo; Paloma García Talavera; Miguel Navarro Martín; Berta Pérez López; María García Muñoz; Pilar Tamayo Alonso; Juan Jesús Cruz Hernández. Large cell neuroendocrine carcinoma of the lung with atypical evolution and remarkable response to lutetium Lu 177 dotatate. *Annals of Nuclear Medicine*; 32(8):568-572, 2018. DOI:10.1007/s12149-018-1276-6.
- Oliver Rúa Fernández; Roberto Escala Cornejo; Miguel Navarro Martín; María García Muñoz; Patricia Antunez Plaza; Rocío García Domínguez; Juan Jesús Cruz Hernández. Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors. *Urology*; 117:41-43, 2018. DOI:10.1016/j.urology.2018.03.032.